Amgen has entered into a new six-year sourcing and supply agreement with DaVita, a kidney-care company based in Denver, Colorado for Amgen’s anemia drugs, Epogen (epoetin alfa) and Aransep (darbepoetin alfa). This agreement is a continuation of Amgen’s and DaVita’s long-term relationship that is focused on serving dialysis patients

Under the new agreement, Amgen will supply DaVita with Epogen and Aranesp in amounts necessary to meet a specified annual percentage of DaVita’s and its affiliates’ requirements for erythropoiesis-stimulating agents used in providing dialysis services in the US and Puerto Rico. The percentage varies during the term of the new agreement from January 6, 2017 through December 31, 2022, but in each year the percentage is at least 90%. The new agreement will replace the sourcing and supply agreement between Amgen and DaVita that began on November 15, 2011 and would have expired on December 31, 2018.

Epogen is indicated for treating anemia due to chronic kidney disease in patients on dialysis to decrease the need for red blood cell transfusion. Aranesp has the same indication, but includes both patients on dialysis and patients not on dialysis.

Source: Amgen